Insider filing · RXRX

Najat Khan sold $549K of Recursion Pharmaceuticals (RXRX)

Executed Dec 22 2025, disclosed Dec 29 2025, 7 days later, against a two-business-day limit.

Returns are measured on stock purchases only.

NK Najat Khan Chief R&D Commercial Officer profile →

Najat Khan (Chief R&D Commercial Officer) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale, 1 filed past the two-business-day deadline), most often in Recursion Pharmaceuticals, Inc. (RXRX). The largest single filing was $549K of RXRX (124,403 sh × $4.41, as filed), executed Dec 22 2025.

RXRX Recursion Pharmaceuticals, Inc. RXRX · Healthcare · 40 filings in 24 months ticker →

Healthcare · Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating techn…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→